Clinicopathological significance of heparanase and basic fibroblast growth factor expression in human esophageal cancer

Table 2 Expression of Hps, bFGF, MVD in esophageal carcinoma.

Parameter	n	Hps			bFGF			MVD
		+	Positiveratio(%)	P	+	Positiveeratio(%)	P	Mean	SD	P
Gender
Male	60	40	66.7	0.787a	43	71.7	0.864a	35.32	7.55
Female	19	12	63.2		14	73.7		37.23	4.17	0.317a
Age (yr)
<60	50	33	66	1a	35	70	0.614a	35.59	3.87	0.876a
≥60	29	19	65.5		22	75.9		36.07	6.11
Tumor cell differentiation
High	27	17	63.0	0.921a	20	74.1		33.13	7.93
Moderate	33	22	66.7		23	69.7	0.918a	31.92	5.29	0.878a
Low	19	13	68.4		14	73.7		32.52	6.17
Depth of invasion
Ti+T1+T2	28	10	35.7	0c	12	42.9	0c	23.78	4.16	0c
T3+T4	51	42	82.4		45	88.2		42.01	5.40
Lymph-node metastasis
N0	32	14	43.8	0.001c	14	43.8		31.87	7.17
N1	47	38	80.9		33	70.2	0.019b	38.44	5.74	0.051a
Clinical stages
0+I+II	38	20	60.5	0.017b	23	60.5		35.95	5.19
II+IV	41	32	70.7		34	82.9	0.026h	43.19	7.15	0.375a

Note:

^aP>0.05 no significant difference;

^cP<0.05 statistical difference;

^bP<0.001 significant difference.